Stay updated on ASCT With Nivolumab in Multiple Myeloma Clinical Trial

Sign up to get notified when there's something new on the ASCT With Nivolumab in Multiple Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ASCT With Nivolumab in Multiple Myeloma Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    A site-wide notice about government funding status was added and the site revision updated from v3.4.0 to v3.4.1.
    Difference
    0.5%
    Check dated 2026-02-04T10:29:40.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    Added a Show glossary feature and updated the site revision to v3.4.0. The label for the last QC update was changed to 'Last Update Submitted that Met QC Criteria' and the 'No FEAR Act data' entry was removed.
    Difference
    0.2%
    Check dated 2026-01-28T06:24:10.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    - Removed related topics: 'Multiple myeloma' and 'MedlinePlus Genetics' from the study page. This may affect searchability and cross-linking to related resources, but does not alter the core trial details.
    Difference
    0.2%
    Check dated 2026-01-21T04:33:15.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    Added related topics including Multiple Myeloma and MedlinePlus Genetics, and updated the page revision to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-14T02:41:23.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    Removed the 'Multiple myeloma' topic and the 'MedlinePlus Genetics' related-topic section from the page.
    Difference
    0.2%
    Check dated 2026-01-07T00:35:20.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    Footer updates include revision note changing to v3.3.3 and removal of the HHS Vulnerability Disclosure link; related topics (MedlinePlus Genetics) were added. Core study details such as condition (Multiple Myeloma), interventions (Nivolumab, Melphalan, autologous stem cell transplantation), and outcomes remain unchanged.
    Difference
    0.3%
    Check dated 2025-12-23T13:26:53.000Z thumbnail image

Stay in the know with updates to ASCT With Nivolumab in Multiple Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ASCT With Nivolumab in Multiple Myeloma Clinical Trial page.